Intranasal oxytocin for autism spectrum disorders (ASD)
Editorial Group: Cochrane Developmental, Psychosocial and Learning Problems Group
Published Online: 20 JAN 2014
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
How to Cite
Feng L, Wong JCM, Mahendran R, Chan ESY, Spencer MD. Intranasal oxytocin for autism spectrum disorders (ASD) (Protocol). Cochrane Database of Systematic Reviews 2014, Issue 1. Art. No.: CD010928. DOI: 10.1002/14651858.CD010928.
- Publication Status: New
- Published Online: 20 JAN 2014
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the efficacy of intranasal oxytocin in improving social interaction and communication deficit, and other clinical outcomes in autism spectrum disorders (ASD), and to examine its safety.